Visiongain predicts total revenues the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027

30 August 2018
Pharma

A new report by visiongain forecasts the world IVD market will reach $122.9bn in 2027. That revenue prediction and others appear in Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia published in November 2016. Visiongain is a business information publisher and consultancy in London, UK.

Visiongain estimates that in 2016, Big Pharma companies, namely Roche, Danaher and Siemens dominated the sector accounting for 41.5% of the global IVD market with combined revenue of $25.7bn

This report analyses the leading companies operating in the in vitro diagnostics (IVD) market. It aims to provide a comprehensive review of those companies, looking at their IVD products, financial performance, deals with other drug developers and future outlooks. The study examines opportunities and challenges in the industry and market for IVD products, as well as strategies for future growth. To provide context for the company profiles, this report also contains analysis of the world IVD market. An estimate for the market size is provided for 2016, and overall market revenues are forecasted for the period 2017 to 2027. Additionally, there is an analysis of the leading IVD segments.

The report focuses on these main segments of the market:

• Clinical Chemistry
• Immunochemistry
• Haematology
• Microbiology
• Genetic Testing
• Point-of-Care

This 185 page report provides:

• Most recent profiles of top In Vitro Diagnostic American Companies with updated revenues and forecast for the period 2017-2027

• Most recent profiles of top In Vitro Diagnostic European Companies with updated revenues and forecast for the period 2017-2027

• Most recent profiles of top In Vitro Diagnostic Asian Companies with updated revenues and forecast for the period 2017-2027

• Enhanced detail analysis of what stimulates and restrains that industry and market.

• 75 figures and 65 tables.

Recent News

“Biological Drug API Manufacturing market set to grow to $11bn by 2025” says Visiongain report

Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes.

07 November 2019

Read

“global radiation oncology market is anticipated to surpass USD 6.5 billion by 2020”, says Visiongain

Growing aging population, urbanization, and growing wealth in low- and middle-income countries such as China and India are anticipated to boost the APAC radiation oncology market.

07 November 2019

Read

“Global Rabies Diagnostics Market is anticipated to surpass USD 1.8 billion by 2020”, says Visiongain

Several international healthcare organizations are working with healthcare organizations to develop and market new detection assays to drive efforts aimed at fighting the disease.

07 November 2019

Read

“Global spinal muscular atrophy (SMA) market is anticipated is to surpass USD 950 Million by 2020”, says Visiongain

Increasing awareness of SMA and increasing numbers of programs to expand treatment options for rare diseases are key factors that are boosting the market growth.

07 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever